ERBB2 and neoplasm: For solid tumors, the origin of the tumor was generally the deciding factor in assessing treatment options, and patients were usually assigned to different treatment options based on primary tumor diagnosis or site, histological subtype, nodal status, hormone receptor and HER2 status for breast and gastro-oesophageal cancers, and KRAS and EGFR status for colorectal and lung cancers, respectively.